Condition: Metastatic Pancreatic Cancer · Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
The aim of this study is to evaluate the efficacy of sequential treatment (Gabrinox) comprising Gembrax regimen (Gemcitabine -Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) compared to folfirinox alone in patients treated in first metastatic line pancreatic cancer
This description comes directly from the study's public registry record.
Aurore MOUSSION, MD · 0467612446 · Aurore.Moussion@icm.unicancer.fr
Fabienne PORTALES, MD · 0467612353 · Fabienne.Portales@icm.unicancer.fr
Always discuss trial participation with your own doctor first.
| CHU Grenoble | Grenoble, Auvergne-Rhône-Alpes, France | Not Yet Recruiting |
| CHU St Etienne | Saint-Etienne, Auvergne-Rhône-Alpes, France | Active Not Recruiting |
| Institut GODINOT | Reims, Grand Est, France | Recruiting |
| CHU St Eloi | Montpellier, Herault, France | Recruiting |
| Institut régional du Cancer de Montpellier | Montpellier, Hérault, France | Recruiting |
| Centre Catalan d'Oncologie | Perpignan, Pyrénées-Orientales, France | Not Yet Recruiting |
| CH de Perpignan | Perpignan, Pyrénées-Orientales, France | Recruiting |
| Centre Georges-François Leclerc | Dijon, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05065801